GovWire

Genetically modified (GM) seed audits are carried out by, or on behalf of, UK authorities in:

• England the Department for Environment, Food and Rural Affairs (Defra)
• Northern Ireland the Department of Agriculture, Environment and Rural Affairs (DAERA)
• Scotland the Scottish Government contact the SASA GMI
• Wales the Welsh Government

Seed audit programme in England

The programme helps companies in England comply with the rules on GMOs in seeds by providing evidence of the actions they take.

The audits include seeds that are to be:

• marketed for commercial production
• used for trial purposes

The audits are carried out by the Animal and Plant Health Agency (APHA) Genetic Modification Inspectorate (GMI) on behalf of Defra.

Taking part in audits is voluntary but you must always follow the relevant legislation and must not import or produce seeds that contain unauthorised GMOs. For more information, read Part VI, Section 8, sub-section (2) of the Environmental Protection Act (1990).

This guide is updated annually before the next round of audits programme begins.

Seed company responsibilities

Companies that import or produce conventional seed in the UK must get consent before they import, acquire, release or market genetically modified organisms (GMOs). Conventional seed means seed produced to relevant certification standards, that is destined for sowing and has not been genetically modified (GM).

They must put appropriate controls in place to minimise the risk of adventitious GM presence (AGMP) (the unexpected, accidental or unplanned occurrence of GM seeds) in the seed for sowing.

Importing or producing seed

You need to show the auditor you have taken action to minimise the risk of AGMP in seed you market or enter into trials.

Crops most at risk of GM presence

The following crop species have been assessed by the GMI as being most at risk of AGMP:

• Brassica napus: winter and spring oilseed rape, swede, swede fodder rape, salad rape, rape or kale hybrids
• Brassica rapa: turnip, turnip fodder rape, stubble turnips, Chinese cabbage, pak choi, oriental greens, rapid-cycling brassicas
• Glycine max: soya bean, edamame
• Zea mays: fodder maize, grain maize and sweetcorn

Control measures to protect seed purity

The main approaches that companies use to protect the purity of their seed in terms of GMOs are production controls and analytical tests.

1. Production controls include:

These include, but are not limited to:

• seed provenance documentation detailing the source of the germplasm, including the breeder and country of origin, and confirmation that the seed has been produced from non-GM lines
• variety maintenance evidence that the variety has been maintained in isolation from transgenic lines (for example by the use of spatial, temporal, physical or procedural methods)
• seed production controls documentation detailing the controls in place to prevent contamination in the field, including at sowing, during the growing or flowering stage, and at harvest
• controls relating to transport, storage and processing documentation confirming the use of suitable measures to prevent the introduction of AGMP due to admixture with other seed (contracted processors should provide written assurances to demonstrate they have appropriate measures in place to minimise the risk of seed acquiring AGMP)

If suppliers request written statements (letters of assurance) as a proxy for direct control or knowledge of production controls, the statements should refer to the specific relevant controls and how they have been applied to the seed.

1. Analytical tests

Analytical tests on individual seed batches or lots, include:

• DNA-based tests, for example, polymerase chain reaction (PCR) tests
• protein-based tests, for example, lateral flow devices (LFDs) or lateral flow tests (LFTs)
• spray tests, for example, for herbicide tolerance

As a minimum, each analytical test should:

• be carried out on a representative sample of the seed lot
• be carried out on a minimum working sample for analysis that contains at least 3000 seeds (which may need to be tested in batches to align with analytical sensitivity)
• include appropriate positive and negative controls
• address the risk of possible false positives
• be conducted to an analytical sensitivity level of at least 0.1% (for example, a limit of detection of less than or equal to 0.1%)
• indicate any standards or accreditation it conforms to, for example ISO17025, United Kingdom Accreditation Service (UKAS), Association Franaise de Normalisation (AFNOR), Good Laboratory Practice (GLP)

Each analytical test should include the result for the test with the associated measurement of uncertainty for the result (for example, plus or minus 95% confidence limits).

For PCR-based tests, the analysis should also include:

• testing with a combination of commonly used promoter and terminator sequences - for example, cauliflower mosaic virus promoter (CaMV p35S) and nopaline synthase terminator (tNOS)
• antibiotic markers appropriate to the crop in question - for example, NptII, the selectable marker for kanamycin resistance

Testing for sequences that encode specific traits such as PAT/BAR (LibertyLink) and GOX (Roundup Ready) may also be appropriate to strengthen the assurance provided by the testing regime.

Assurances should be provided on the separate handling of the seed subsequent to any testing. Test certificates should clearly identify the lots or batches they refer to.

Mutagenesis and gene-editing

In April 2022, the law changed regarding genetically modified plants under the Genetically Modified Organisms (Deliberate Release) (Amendment) (England) Regulations 2022). These changes affect field trials for research and development only and not commercialisation or marketing. These plants are described as qualifying higher plants, material from which must not be allowed to enter the human food chain or fed to animals.

The Genetic Modification Inspectorate carries out inspections of Genetically Modified Organism field trials in accordance with the powers granted under the Environmental Protection Act 1990, including for qualifying higher plants where there is a possibility of non-compliance.

On 25 July 2018, the European Court of Justice (case C-528/16) ruled that the use of certain gene editing techniques, such as oligonucleotide-directed mutagenesis (including CRISPR-Cas9 techniques), constitute genetic modification. This means that all organisms produced by gene-editing techniques must be regulated as GMOs.

Plant varieties produced in the EU using these techniques need to go through the EU authorisation process before being marketed or commercially cultivated in the EU and Northern Ireland.

In Great Britain, separate authorisations are required for the import, acquisition, release or marketing of GMOs in England, Scotland and Wales.

Before the ruling some breeders were known to be preparing to market varieties produced using these now-regulated techniques. The GMI does not believe that any such products have been marketed in the EU. However, companies should remain vigilant to the potential use of regulated gene-editing techniques

View the original news story